[Interleukin-1 in combined detoxification therapy of surgical sepsis].
Clinical trials of Russian yeast recombinant human interleukin-2 (yrIL-2) were carried out in 17 patients with posttraumatic and postoperative sepsis to whom 33 intravenous drip infusions of the drug were administered as a single infusion or courses of 2 to 4 injections in a dose of 1,000,000 U per .1 m2 body surface. A positive clinical effect of yrIL-2 in this dose was observed on the next day after the first injection of the drug: the signs of intoxication were reliably reduced. The immunostimulating effect of yrIL-2 consisted in activation of pharmacytizing leukocytes of blood. Addition of yrIL-2 to therapeutic complex for patients with sepsis helped reliably reduce the mortality of such patients with sepsis helped reliably reduce the mortality of such patients to 29.4% vs. 63.3% in controls.
Grinev
M V
MV
Gromov
M I
MI
Tsibin
Iu N
IuN
Tarelkina
M N
MN
Shirokov
D M
DM
Pivovarova
L P
LP
Razumova
N K
NK
Masilianskaia
T I
TI
Ariskina
O B
OB
Guĭda
O G
OG
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007376:Interleukin-2 / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000188:drug therapy* / Q000401:mortality; D018805:Sepsis / Q000188:drug therapy* / Q000209:etiology / Q000401:mortality; D013997:Time Factors
D007376:Interleukin-2
Interleĭkin-2 v kompleksnoĭ detoksikatsionnoĭ terapii khirurgicheskogo sepsisa.